Arcus Biosciences (RCUS) Expected to Announce Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS) will likely be announcing its earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of ($1.20) per share and revenue of $31.31 million for the quarter.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $11.99 on Wednesday. The company has a market cap of $1.10 billion, a PE ratio of -3.81 and a beta of 0.84. Arcus Biosciences has a 52 week low of $11.89 and a 52 week high of $20.31. The business has a 50 day moving average price of $14.78 and a 200-day moving average price of $15.75. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Analysts Set New Price Targets

Several research firms have recently issued reports on RCUS. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. Barclays upped their target price on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $20.00 target price on shares of Arcus Biosciences in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $32.67.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the transaction, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.30% of the stock is owned by corporate insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.